Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
McKesson
Moodys
Express Scripts
Mallinckrodt

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. )

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Small Molecule Drugs cited in OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. )

Date Filed Document No. Description Snippet Link To Document
2015-06-22 127 various patents covering Otsuka’s Abilify® aripiprazole product, U.S. Patent Nos. 8,017,615 (“the ’…primary compound patent for Abilify, U.S. Patent No. 5,006,528 (hereinafter, the “’528 Patent”), and because… ’615 patent”) and 8,580,796 (“the ’796 patent”). Otsuka now moves to dismiss Torrent’s Fifth…for trial the patent issues raised in this litigation from the antitrust and/or patent misuse issues… 355(j), Otsuka identifies the ’615 patent and the ’796 patent, both of which Otsuka owns by virtue External link to document
2015-09-25 152 include: U.S. Patent Nos. 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (… (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“the…the ’760 patent”), and 8,759,350 (“the ’350 patent,” and collectively, the “patents-in-suit”). …various patents covering Otsuka’s brand name aripiprazole product, Abilify®. 1 1 The patents asserted…Local Patent Rules, the Court explains at the outset the overall structure of the Local Patent Rules External link to document
2015-11-16 166 various patents covering Otsuka’s Abilify® aripiprazole product, U.S. Patent Nos. 5,006,528 (“the …the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“the ’796…796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“the ’760 patent”), and 8,759,350 (“the ’…identifies the ’528 Patent, the primary aripiprazole compound patent, as well the ’600 Patent, which claims…The ’350 Patent: Otsuka’s Asserted Method of Use Patent The ’350 Patent, by contrast External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.